Robust itemizing for the biotech agency alerts investor pleasure. Valuation, although, raises eyebrows.
Anthem Biosciences pops 27% on debut. However is it too expensive?

Leave a comment
Robust itemizing for the biotech agency alerts investor pleasure. Valuation, although, raises eyebrows.
Sign in to your account